The Clinical Performance of Narrow Diameter Implants Versus Regular Diameter Implants: A Meta-Analysis.

The purpose of this study is to analyze 1- and 3-year clinical performances of narrow diameter implants (NDIs) versus regular diameter implants (RDIs). A search of electronic databases and a manual search was performed for the time period January 2000 to April 2018. A meta-regression was used to evaluate the effects of the "fixed effects" model on the implant survival rates, prosthesis success rates and marginal bone loss (MBL) with follow-up time of 1 year and 3 years. Of the 11 studies included, the overall combined 1-year implant survival rates were 98.14% for NDIs and 98.20% for RDIs. The overall combined 3-year implant survival rates were 98.71% for NDIs and 98.84% for RDIs. The corresponding values for 1-year prosthesis success rates were 96.94% for NDIs and 99.25% for RDIs. The corresponding values for 3-year prosthesis success rates were 89.25% for NDIs and 96.55% for RDIs. The meta-regression showed no significant differences between NDIs and RDIs regarding implant survival rates, prosthesis success rates, and MBL in 1-year and 3-year follow-up (P > .05). The results of this meta-analysis concluded that the implant diameter did not affect its survival rates, prosthesis success rates, and MBL in 1 and 3 years. The use of NDIs instead of bone augmentation procedures with RDIs did not affect its survival rates, prosthesis success rates, and MBL in the short-term and middle-term. However, more high-quality randomized controlled trials and long follow-up studies are needed on this topic.

Real time detection of glutathionse in chemotherapy squamous-cell carcinoma cells of a fluorescent probe.

Glutathione (GSH) plays a key role in protecting damage induced by radiation and chemotherapy drugs. Current methods, which quantify GSH level changes by using cellular extraction or being based on redox homeostasis results, are unable to directly measure real time GSH level in live cells. In this article, we utilized a newly designed reversible fluorescent probe to measure GSH in living cells. The image of probe 1 can reveal intracellular GSH location and GSH level changes caused by different chemotherapy drugs in squamous-cell carcinoma cells. The results show that it is the first report with probe 1 that to quantify real-time GSH level changes in the cultured chemotherapy cancer cells and different changes in GSH level that may confer chemotherapy resistance.